ACIP Reports on First “Do-It-Yourself at Home” Nasal Flu Shot
In September 2024, the U.S. Food and Drug Administration (FDA) licensed the first of its kind live attenuated nasal spray influenza vaccine to be administered at home during the 2024-2025 “flu season.” Adults up to the 49 years of age are eligible to self-administer the FluMist Home vaccine or give it to their children aged […]
Meet the Latest Vaccine Propagandist
In case you were not aware, MedPage is a pharmaceutical industry-funded marketing (synonym: Propaganda) operation posting as an objective source of medical truth. On January 05, 2024, this Pharma Propaganda outlet published a video interview with Dr. Paul Offit, professional academic pediatrician and vaccine shill, in which he states a series of falsehoods in continuation […]
Flu Shot Recipients “More Likely” to Get Influenza Than Unvaccinated
The American Medical Association (AMA) cites that the influenza vaccine is estimated to be 40-60 percent effective at preventing serious infections or death from the influenza virus that affects up to 40 million Americans every year. However, for the 2024-2025 flu “season” the influenza vaccine not only missed the mark on effectiveness, but is linked […]
CDC’s ACIP Forms Workgroup to Back New Lyme Disease Vaccine and Monoclonal Antibody Products
At an Apr.15-16, 2025 meeting of the U.S. Centers for Disease and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), it was announced that a workgroup had been formed to further development of a new vaccine for Lyme disease. The first session of the new group will take place in May with a presentation scheduled […]
HHS Halts Funding for Development of Next-Generation COVID Biologics
The U.S. Department of Health and Human Services (DHHS) has stopped U.S. government funding for the development of next-generation COVID-19 biologics by two companies, GeoVax, Inc. of Atlanta, Georgia and CastleVax, Inc. of New York. The project had been funded by Project NextGen, a Biden administration initiative under the U.S. Center for the Biomedical Advanced […]
Guillain-Barré Syndrome Warning Added to Shingrix Vaccine in Australia
In February 2024, Australia’s Therapeutic Goods Administration (TGA), the country’s national regulatory authority for drugs and, initiated an investigation into a potential association between GSK plc’s Shingrix shingles vaccine, Guillain-Barré syndrome (GBS), which causes inflammation and damage to the nerves, that may include paralysis.1 The investigation was prompted by two reports of GBS following Shingrix […]